Back

Samsung Biologics defends 3 trillion won rights offering for 15.4 trillion plan

Verifying
  • Samsung Biologics approved a rights offering to fund PolyPeptide and Plant 6 investments.
  • 3.0009 trillion won will be raised, including 2.7062 trillion won for PolyPeptide.
  • The company will revisit dividends and shareholder returns in three years.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.